The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non–small cell lung cancer (NSCLC) treated with definitive radiation therapy.
 
Emily S. Lebow
Stock and Other Ownership Interests - Oncia Technologies
 
Yonina R. Murciano-Goroff
Honoraria - Virology Education
Research Funding - Elucida Oncology (Inst); Loxo/Lilly (Inst); Taiho Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Justin Jee
Patents, Royalties, Other Intellectual Property - Patient license, MDSeq Inc
 
Ekaterina Kalashnikova
Employment - Natera
Stock and Other Ownership Interests - Natera
Travel, Accommodations, Expenses - Natera
 
Jordan Feeney
Stock and Other Ownership Interests - Natera
Travel, Accommodations, Expenses - Natera
 
Himanshu Sethi
Employment - Natera
Stock and Other Ownership Interests - Natera
Research Funding - Natera
Patents, Royalties, Other Intellectual Property - Patents
Travel, Accommodations, Expenses - Natera
 
Alexey Aleshin
Employment - Natera; Natera
Leadership - Natera
Stock and Other Ownership Interests - Natera
Consulting or Advisory Role - Mission Bio; Mission Bio
Travel, Accommodations, Expenses - Natera
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca; Janssen; Pfizer
Travel, Accommodations, Expenses - Genentech
 
Jamie E. Chaft
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Flame Biosciences; Genentech/Roche; Guardant Health; Janssen Oncology; Merck; Novartis; Sanofi/Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst)
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bridge Medicines; Daiichi Sankyo/UCB Japan; Earli; Epizyme; Genentech/Roche; Harpoon Therapeutics; Ipsen; Jazz Pharmaceuticals; Kowa; Merck; Syros Pharmaceuticals; Syros Pharmaceuticals
Research Funding - Merck (Inst); Roche/Genentech (Inst)
 
David Randolph Jones
Consulting or Advisory Role - AstraZeneca; Merck
 
Pedram Razavi
Honoraria - Daiichi Sankyo/Lilly; Epic Sciences; Guardant Health; Inivata; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Foundation Medicine; Guardant Health; Inivata; Natera; Novartis; Tempus
Research Funding - Archer (Inst); AstraZeneca (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Illumina (Inst); Novartis (Inst); Tempus (Inst)
 
Jorge S. Reis-Filho
Leadership - Grupo Oncoclinicas
Stock and Other Ownership Interests - PAIGE.AI; Repare Therapeutics
Consulting or Advisory Role - Genentech/Roche; Goldman Sachs; Invicro; Lilly; Novartis; Paige.AI; Personalis; Repare Therapeutics; Ventana Medical Systems; Volition RX
 
Daniel Richard Gomez
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck; Reflexion Medical; US Oncology; Varian Medical Systems; Vindico Medical Education
Consulting or Advisory Role - Olympus Medical Systems
Research Funding - AstraZeneca; Bristol-Myers Squibb; Merck; Varian Medical Systems
Travel, Accommodations, Expenses - AstraZeneca; Driver, Inc; Merck; US Oncology; Varian Medical Systems; Vindico Medical Education
 
Daphna Y. Gelblum
No Relationships to Disclose
 
Narek Shaverdian
Research Funding - Novartis (Inst)
 
James M. Isbell
Stock and Other Ownership Interests - LumaCyte
 
Bob T. Li
Research Funding - Ambrx (Inst); Amgen (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Hengrui Therapeutics (Inst); Lilly (Inst); MORE Health (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Karger Publishers - Book royalty; Shanghai Jiao Tong University Press - Book royalty; US62/514,661 (Inst); US62/685,057 (Inst)
Travel, Accommodations, Expenses - Jiangsu Hengrui Medicine; MORE Health
(OPTIONAL) Uncompensated Relationships - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Genentech; Lilly
 
Andreas Rimner
Honoraria - More Health
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Pfizer (Inst); Varian Medical Systems (Inst)